ReviewAAPS PharmSciTech2021
Nanoparticle-Based Delivery to Treat Spinal Cord Injury-a Mini-review.
Review in AAPS PharmSciTech, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Systematic Review of Peptide CAQK: Properties, Applications, and Outcomes.International journal of molecular sciences · 2024Pooled it
- Current Advancements in the Arsenal for Spinal Cord Injury Repair: Novel Drug Formulations.International journal of nanomedicine · 2026Review
- Copper-regulated cell death after spinal cord injury: evidence boundaries for non-coding RNA, epigenetics and cuproptosis.Frontiers in molecular neuroscience · 2026Review
- Galantamine-loaded PLGA nanoparticles reduce oxidative stress and inflammation in a rat model of spinal cord injury.Scientific reports · 2025Article
- Immunomodulatory Biomaterials for Bone and Soft Tissue Chronic Inflammation Diseases.Small science · 2025Review
- Early nanoparticle intervention preserves motor function following cervical spinal cord injury.Bioengineering & translational medicine · 2025Article
- Unveiling the effects ofFrontiers in pharmacology · 2025Article
- Advancements in Antioxidant-Based Therapeutics for Spinal Cord Injury: A Critical Review of Strategies and Combination Approaches.Antioxidants (Basel, Switzerland) · 2024Review
- Delivery of TGFβ3 from Magnetically Responsive Coaxial Fibers Reduces Spinal Cord Astrocyte Reactivity In Vitro.Advanced biology · 2024Article
- Development of Combinatorial Therapeutics for Spinal Cord Injury using Stem Cell Delivery.Journal of visualized experiments : JoVE · 2024Article
- Review
- The therapeutic potential of microRNAs to ameliorate spinal cord injury by regulating oligodendrocyte progenitor cells and remyelination.Frontiers in cellular neuroscience · 2024Review
- Barrier-penetrating liposome targeted delivery of basic fibroblast growth factor for spinal cord injury repair.Materials today. Bio · 2023Article
- Biomaterial-targeted precision nanoparticle delivery to the injured spinal cord.Acta biomaterialia · 2022Article
- Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment.Biomedicines · 2022Review
- Optimization of the Duration and Dose of Photobiomodulation Therapy (660 nm Laser) for Spinal Cord Injury in Rats.Photobiomodulation, photomedicine, and laser surgery · 2022Article
- Therapy of spinal cord injury by zinc modified gold nanoclusters via immune-suppressing strategies.Journal of nanobiotechnology · 2021Article
- National Institute for Pharmaceutical Technology & Education (NIPTE) Research and Perspective: Advances in Nanotechnology-Based Drug Delivery.AAPS PharmSciTech · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
There is an increasing need to develop improved and non-invasive strategies to treat spinal cord injury (SCI). Nanoparticles (NPs) are an enabling technology to improve drug delivery, modulate inflammatory responses, and restore functional responses following SCI. However, the complex pathophysiology associated with SCI presents several distinct challenges that must be overcome for sufficient NP drug delivery to the spinal cord. The objective of this mini-review is to highlight the physiological challenges and cell types available for modulation and discuss several promising advancements using NPs to improve SCI treatment. We will focus our discussion on recent innovative approaches in NP drug delivery and how the implementation of multifactorial approaches to address the proinflammatory and complex immune dysfunction in SCI offers significant potential to improve outcomes in SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.